Pfizer leans on a $10.5 billion oncology partnership as investors gauge dividend risk from the coming patent cliff

Pfizer’s dividend debate is returning to the center of investor attention as the company works through what Wall Street calls a “patent cliff” - a period when drugs lose patent or exclusivity protection and sales pressure typically follows. In a recent market report, The Motley Fool pointed to Pfizer’s post–COVID revenue decline and highlighted that several top products are approaching the end of patent protection, framing the question as whether the cash flow needed for ongoing dividend payments can be sustained. The Motley Fool

Pfizer is still paying a quarterly cash dividend at the current rate. The company’s board declared a first-quarter 2026 dividend of $0.43 per share, payable March 6, 2026, and said it would be the 349th consecutive quarterly dividend. Pfizer dividend declaration

The market concern is timing: in the same report, The Motley Fool cited that Pfizer’s high-selling medicines - including blood thinner Eliquis and the cancer drugs Ibrance and Xtandi - are expected to lose patent protection in the coming period, with those three products together accounting for more than $20 billion of 2025 revenue. That concentration increases the stakes for how quickly Pfizer can refill demand with newer therapies. The Motley Fool

To address longer-term oncology needs without relying on a single blockbuster pathway, Pfizer announced a strategic global licensing and collaboration agreement with Innovent Biologics covering 12 early-stage and “de novo” (newly generated) cancer medicines. Pfizer said the portfolio includes eight programs originating from Innovent and four discovery programs proposed by Pfizer, spanning antibody-drug conjugates (ADCs) - a class that couples an antibody to a drug payload - with multi-specific antibodies designed to engage the immune system in distinct ways. Pfizer press release

The deal’s financing is structured to limit near-term cash risk: Innovent will receive a $650 million upfront payment and be eligible for up to $9.85 billion in additional development, regulatory, and commercial milestone payments; Pfizer also said Innovent could receive up to double-digit royalties on sales if products are approved. Pfizer further said Innovent will conduct development through Phase 1, after which Pfizer will lead future global development, and that the transaction is expected to close in the third quarter subject to regulatory approvals. Pfizer press release

Even with that milestone-heavy structure, investors will likely focus on whether Pfizer can convert pipeline activity into cash flows at a pace sufficient to support shareholder returns through the patent cliff years. The Motley Fool argued that partnerships like this can provide “lower-cost” growth compared with large acquisitions, but also cautioned that Pfizer still faces meaningful leverage and spending demands, and that the company’s longer-term payout sustainability will depend on clinical and regulatory execution. The Motley Fool